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Aim: recent progresses in molecular biology have been 
made in the diagnosis of sensorineural hearing loss. The 
high prevalence of a connexin 26 gene mutation, and its 
easy identification have made the diagnosis possible. The 
most frequent gene mutation is called 35delG. The purpose 
of this study was to evaluate the prevalence of 35delG 
mutation in children submitted to cochlear implantation who 
had severe and profound hearing loss previously diagnosed 
as idiopathic. Method: The study was done at the Cochlear 
Implantation Clinic of the Otolaryngology Department and 
at the Laboratório Genética Humana-CBMEG, UNICAMP-SP. 
32 children with severe to profound sensorineural hearing 
loss were evaluated. The detection of the 35delG mutation 
was made by a allele -specific PCR, using primers and 
polymerase chain reaction. Results: 69% had a normal exam, 
12% were homozygous for the mutation, 19% of the cases 
were heterozygous. The 35delG mutation in heterozygousity 
is not a cause of hearing loss. Conclusion: The data confirm 
the high prevalence of the 35delG mutation in nonsyndromic 
bilateral profound sensorineural hearing loss. It was also 
possible to diagnose the cause of hearing loss as genetic 
in a significant percentage of patients. That stresses the 
importance of the molecular investigation in those cases 
formerly classified as idiopathic.
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INTRODUCTION
In developed countries, it is estimated that 60% of 
the cases of prelingual deafness have genetic causes, and 
the remaining 40% have the most varied etiologies (Ma-
razita et al., 1993, Mustafa et al., 2001). Moreover, 1/1000 
children become deaf after learning to speak, before co-
ming of adult age; between 30-50 years of age, 0.3% of the 
population report hearing loss above 65 decibels (dB) and 
2.3% of the population have it between 60 and 70 years 
of age. The prevalence keeps growing and continues to 
increase, reaching 50% in 80 year old patients (Paparella 
et al., 1989; Morton et al., 1991).
In Brazil, environmental factors (67%) are among the 
major causes of hearing loss, mostly congenital rubella and 
neonatal anoxia (33.5%), followed by those of unknown 
etiology (18.5%) and those of recessive autosomal heritage 
(15.5%). With the major environmental factors, high deaf 
risk neonates are those with a 2-5% chance of developing 
hearing loss if they suffer one or more of the following 
factors: asphyxia or anoxia, with Apgar score below 7,1; 
bacterial meningitis, specially caused by Haemophilus 
influenza; prenatal congenital infections (syphilis, toxoplas-
mosis, rubella, cytomegalovirus, herpes); head and neck 
malformations; high bilirubin levels (levels that require 
transfusion); family history of hearing loss; neonatal ICU 
stay for more than 48 hours; birth weight below 1.5 kilo-
gram and use of ototoxic drugs by the pregnant mother 
or during the neonatal period (Simões et al., 1992).
Cases of late hearing loss, that being, postlingual, 
may also occur after exposure to ototoxic drugs, family 
history of hearing loss, and in some cases it may be a 
sudden hearing loss of unknown origin, thus being con-
sidered idiopathic. 
Although genetic therapy is still far from practical 
use, cochlear implants are a feasible resource, and one 
available for bilateral severe/or profound hearing loss for 
those who do not benefit from individual sound amplifi-
cation devices (hearing aids). 
In those cases of patients who lost hearing before 
learning to speak (prelingual), age is one of the most 
important factors. In very young patients, results are 
better than in older children. Usually the cause of this 
early hearing loss is congenital, of genetic origin, without 
physical injury to the hearing apparatus, and this favors 
the cochlear implant. 
The 35delG mutation on the connexin 26 gene is 
not rare; and quite the contrary, its presence in hetero-
zygosis may be found in up to 3% of the individuals of 
some populations. Notwithstanding, in Italy, its prevalence 
is around 1:32, in Portugal it is of 1:40, and in Spain it is 
1:45. If we group together these three European popu-
lations, of which a great part of the Brazilian population 
descend, we can see that the average frequence of hete-
rozygosis for the 35delG mutation is of 1:42; considering 
a random union of heterozygosis and the 25% chance of 
affected descendents, we know that in these regions 1 in 
5,069 children would be born deaf because of the 35deIG 
mutation homozygosis (Gasparini et al., 2000).
Recent progresses in molecular biology, with the 
finding of different genes involved in hearing loss, allow 
the possibility of identifying the hearing loss etiology. The 
high prevalence of mutations on the GJB2 gene and the 
ease of study allow the diagnosis of many a patient, and 
have suggested that these individuals would be potential 
candidates to receive a cochlear implant. 
The most frequent mutation in this gene is the one 
called 35delG, the one most involved in cases of hearing 
loss of genetic etiology. 
This mutation is the loss of a guanine base in the 
DNA sequence of the gene on position 35. It is very im-
portant to search for the 35delG mutation in the hearing 
loss etiology, since 2 to 4% of the individuals are carriers 
of this mutation, in other words, they are heterozygotes. 
The 35delG mutation corresponds from 75 to 80% of the 
possible mutations found in this gene (Cohn, et al., 1999a; 
Cohn et al., 1999b).
It is necessary for the individual to inherit two mu-
tated genes, one from the father and the other from the 
mother, for deafness to set in. This way, it is impossible 
for connexin 26 to be codified by the altered GJB2 gene. 
When the patient presents a 35delG mutation in hetero-
zygosis, it means that there is mutation in only one of the 
alleles, and thus it is possible for the other allele to codify 
the protein. This implies in a smaller number of codified 
connexin 26.
The connexin 26 protein is indispensable to the nor-
mal functioning of the inner ear, and the gene alterations 
responsible for its coding is the main cause of hereditary, 
non-syndromical prelingual deafness, identified by the 
35delG mutation study through the “genetic hearing loss 
test”.
Some studies have concluded that the cochlear 
implant in patients with GJB2 gene-related hearing loss 
allows them to acquire voice recognition equal to or better 
when compared to prelingual deaf children, with deafness 
of unclear origin, or even with congenital hearing loss, 
such as those caused by cytomegalovirus (Sinnathuray et 
al., 2004; Green et al., 2002). This is so, because when 
the damage occurs to the gene, its expression does not 
interfere in the placement of the implant, in other words, 
the cochlea is not involved, such is the case of traumatic 
or infectious hearing loss, from meningitis or ototoxicity, 
which damages the cochlear physical structure, often times 
preventing a larger number of electrodes to be inserted 
because of cochlear calcification, for instance. Genetic 
damage happens to the connexons structure, impairing 
intercellular communication, and this does not harm the 
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cochlear physical structure, favoring the implant. 
The feasibility and the benefits of tracking the 
connexin 26 gene mutations are being reflected on public 
health. The use of molecular tests, together with audiome-
tric tests will help in the early detection of hearing loss, 
which is extremely important in managing these patients, 
specially in cases of progressive hearing loss, since langua-
ge development in its critical period makes the children 
learn to communicate before the hearing loss becomes 
more severe. Moreover, today it is possible to make a 
predictive diagnosis in those individuals affected by mu-
tations in the connexin 26 gene, even before hearing loss 
sets in. The consequences of this prediction in both the 
social and family environment are deafness prevention or 
to help reduce costs assigned to the special education of 
such individuals, its medical management and professional 
decision (Sobe et al., 2000; Sartorato et al., 2000).
The goal of the present work was to check the 
incidence of 35delG mutation in children in need of and 
who received cochlear implants and had their hearing loss 
diagnosed as supposedly idiopathic. 
MATERIALS AND METHODS
This study was carried out in the otorhinolaryngolo-
gy outpatient ward of the University Hospital -  UNICAMP-
SP, cochlear implant and human genetics lab departments  
CBMEG, UNICAMP-SP.
32 children candidates to cochlear implantation, 
with sensorineural, severe to profound, supposedly idio-
pathic, bilateral hearing loss.  The major inclusion criteria 
of these children in the cochlear implant department are 
the non-benefit of individual sound amplification device 
(hearing aids). These individuals were submitted to a 
multiprofessional assessment, including otorhinolaryngo-
logists, speech therapists, psychologists, social workers, 
nurses and geneticists. 
The 35delG mutation tracking was carried out based 
on peripheral blood DNA colected in a purple lid Vacutai-
ner. In order to detect the 35delG mutation we used the 
allele specific PCR method (AS-PCR), using primers and 
the aforementioned polymerase chain reaction - modifi-
cation patented by CBMEG - UNICAMP. (Oliveira et al., 
2002). This method easily differentiates the normal allele 
from the mutant and through two reactions it is possible 
to distinguish normal homozygotes, 35delG homozygote 
and heterozygote carriers of the 35delG mutation. 
The molecular analysis results were correlated 
with the hearing loss etiology presented by the patients 
analyzed. 
RESULTS
In the present study, 32 children with idiopathic 
hearing loss underwent GJB2 gene 35delG mutation tra-
cking.  The mutation was found in 4 homozygotes of the 
total children assessed (12% of the cases), this being the 
hearing loss cause. The mutation was found in heterozygo-
sis in 6 children (19% of the cases); It was not possible to 
diagnose the hearing loss in these patients. The 35delG 
heterozygosis mutation does not diagnose the hearing loss 
cause, it only proves the patient is a carrier of the mutation 
and, as shown in the literature, heterozygote patients can 
always hear. In the graph below, we can see the results 
obtained from the genetic study.
DISCUSSION
With the progress of research in this area, it is clear 
the importance of gjb2 gene mutation studies due to the 
Chart 1.
easy detection of mutations in the conexine 26, specially 
mutation on 35delg - considered the most frequent muta-
tion of any gene already studied in caucasoids. This is the 
first gene indicated for molecular analysis in families with 
sensorineural hearing loss (sobe et al., 2000).
In a prior study carried out in a sample of the Brazi-
lian population, mutations to the GJB2 gene were found in 
22% of the families with non-syndromical sensorineural he-
aring loss, once again pointing out that molecular analysis 
of this gene in patients with non-syndromical hearing loss 
should be the first step in determining hearing loss causes 
in our country (Oliveira et al., 2001). This is particularly 
true for cases of family hearing loss, among which the fre-
quence of mutations in this gene was found to be of 50%, 
but also for sporadic cases, among which the frequence 
was a bit higher than 11% (approximately 1:9) (Oliveira 
et al., 2002). In Brazil, the prevalence of 0.97% of 35delG 
mutation carriers was found to be approximately 1:103 
heterozigotes, in a survey carried out with 620 newborns 
in the region of Campinas-SP (Oliveira et al., 2004).
Our results are in agreement with studies carried 
out and described in the literature for different popula-
tions. The relative distribution of the 35delG mutation for 
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non-syndromical hearing loss in these populations varied 
from 0% (Oma, Korea and Japan) to 70% (Italy, Spain, 
Greece), showing the genetic heterogeneity among the 
different countries, despite the fact that some of these 
studies were based on a small number of patients and the 
investigation criteria regarding mutation tracking methods 
were different as well. 
CONCLUSION
Data obtained in the present study confirmed the 
high prevalence of GJB2 gene 35delG mutation in cases 
of profound and bilateral non-syndromical sensorineural 
hearing loss. It is also possible to use genetics to diag-
nose the cause of hearing loss in a significant number of 
children. 
The results stress the importance of molecular stu-
dies in patients with supposedly idiopathic hearing loss, 
since this test allows us to clarify the hearing loss etiology 
when there is a positive result. 
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